Intralesional BCG in the treatment of metastatic malignant melanoma

The therapeutic efficacy of intralesional BCG (Bacillus Calmette‐Guerin; one immunizing dose every 2 weeks for a minimum of five treatments) was studied in 19 melanoma patients. Of 15 patients evaluable for response, five experienced significant objective improvement (two complete and three partial remissions). Objective improvement was limited to those patients with dermal metastatic disease. In vitro cytotoxicity in the presence of patient's serum bore, on average, a relationship to the clinical disease. In certain individual cases, serum blocking and/or lymphocyte stimulation may have had prognostic significance.

[1]  M. Mastrangelo,et al.  Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. , 1974, American journal of clinical pathology.

[2]  M. Mastrangelo,et al.  Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report. , 1974, Journal of the National Cancer Institute.

[3]  M. Mastrangelo,et al.  Immunotherapy of melanoma with intralesional BCG. , 1973, National Cancer Institute monograph.

[4]  Y. Hirshaut,et al.  Treatment of malignant melanoma by intratumoral injection of BCG. , 1973, National Cancer Institute monograph.

[5]  G. Heppner,et al.  Cell‐mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma , 1973, International journal of cancer.

[6]  I. Hellstrom,et al.  Sequential studies on cell‐mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma , 1973, International journal of cancer.

[7]  K. Hellström,et al.  Some recent studies on cellular immunity to human melanomas. , 1973, Federation proceedings.

[8]  L. Nathanson.  Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. , 1972, Cancer chemotherapy reports.

[9]  I. Bernstein,et al.  Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. , 1972, Journal of the National Cancer Institute.

[10]  J. Bernheim,et al.  Cytotoxic lymphocytes in melanoma patients , 1972 .

[11]  B. Giovanella,et al.  Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. , 1972, Journal of the National Cancer Institute.

[12]  R. Prehn.  The Immune Reaction as a Stimulator of Tumor Growth , 1972, Science.

[13]  D. Morton.  Immunological Studies with Human Neoplasms1 , 1971 .

[14]  I. Bernstein,et al.  Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. , 1971, Journal of the National Cancer Institute.

[15]  H. Sjögren,et al.  Demonstration of cell‐mediated immunity to human neoplasms of various histological types , 1971, International journal of cancer.

[16]  B. Zbar,et al.  Immunotherapy of Cancer: An Experimental Model in Syngeneic Guinea Pigs , 1970, Science.